Q2 2026
Released Aug 13, 2026, after the close
10-Q filed Aug 13, 2026, 44 days after period end · 0001789769-26-000057
Q2 2026 · 10-Q
Revenue—
Net Income-$4.42M-$4.42M N/M vs Q2 2025N/M vs Q1 2026
EPS Diluted-$0.65-$0.65 N/M vs Q2 2025N/M vs Q1 2026
Operating Income-$6,162,000N/M
Operating Cash Flowderived-$4,642,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$4.42M | -$21.39M | -$14.92M | -$18.66M |
| EPS Diluted | -$0.65 | -$3.24 | -$2.29 | -$2.87 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Instil Bio, Inc. · CIK 1789769 · Engraved from SEC EDGAR